NCT01418651View on ClinicalTrials.gov

Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

PHASE3TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Fibromyalgia
Interventions
DRUG

Savella

milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)

Trial Locations (1)

85351

Banner Sun Health Research Institute, Sun City

Sponsors

Lead Sponsor

Banner Health

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Banner Health

OTHER

NCT01418651 - Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population | Biotech Hunter | Biotech Hunter